Novo Nordisk is preparing to launch its blockbuster obesity drug Wegovy (injectable semaglutide) in India later this year, ...

Novo Nordisk today announced the following changes in Executive Management. After a distinguished career of 28 years with ...

Novo Nordisk is shaking up its executive team as it bids adieu to its longtime head of commercial strategy and corporate ...

Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest ...

Bagsværd: Novo Nordisk HA has announced that Camilla Sylvest has decided to leave the company after a distinguished career of ...

Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Helge Lund, chair of the Board of Directors ...

Based on data from the SOUL clinical trial, Novo Nordisk submitted a label extension application for Rybelsus ®, which has been accepted for review by the European Medicines Agency (EMA) and the US ...

Copenhagen, DENMARK — Novo Nordisk defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss ...